In a nutshell This study examined how safe and effective brentuximab vedotin (Adcedris) is when added to conventional treatments for relapsed and unresponsive Hodgkin lymphoma. This study concluded that this treatment is safe and effective when used as part of the treatment for Hodgkin lymphoma. Some background Standard treatment for...
Read MoreCurrent disease status-First occurrence of the lymphoma Posts on Medivizor
Reviewing treatment strategies for early-stage Hodgkin lymphoma
In a nutshell This article reviews treatment strategies for patients with early-stage (stage 1 – 2) Hodgkin lymphoma (HL). Some background One of the main treatment goals for patients with HL is to improve long-term outcomes. However, many patients experience complications decades after initial treatment. These may include secondary cancer...
Read MoreSintilimab in relapsed or unresponsive Hodgkin lymphoma
In a nutshell This study examined the safety and effectiveness of sintilimab in patients with relapsed or unresponsive Hodgkin lymphoma. This study concluded that sintilimab could be a new treatment option for these patients. Some background Hodgkin disease (HD) is a type of lymphoma. In patients who relapse or do not respond to first-line...
Read MoreLong-term outcomes of radioimmunotherapy for patients with follicular lymphoma
In a nutshell This study evaluated the long-term outcomes of radioimmunotherapy (RIT) in patients with follicular lymphoma (FL). This study concluded that RIT is a safe and effective long-term treatment option for these patients. Some background FL is the most common type of non-Hodgkin’s lymphoma. The current standard first-line treatment for...
Read MoreEvaluating BEAM conditioning for allogeneic stem cell transplantation in patients with relapsed or unresponsive lymphoma
In a nutshell This study evaluated the effectiveness and safety of BEAM (carmustine, etoposide, cytarabine, and melphalan) chemotherapy before allogeneic hematopoietic cell transplantation (alloHCT; transferring healthy cells from a donor) for relapsed or unresponsive lymphoma. This study concluded that alloHCT with BEAM chemotherapy is an alternative...
Read MoreEvaluating the safety of EPOCH-R therapy for patients with non-Hodgkin’s lymphoma
In a nutshell This study investigated complications associated with reduced-intensity EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) therapy for patients with non-Hodgkin’s lymphoma (NHL). This study concluded that this treatment was associated with high rates of drug delivery complications. Some background...
Read MoreEvaluating front-line allogeneic stem cell transplantation for mantle cell lymphoma
In a nutshell This study evaluated the outcomes of patients with mantle cell lymphoma (MCL) after front-line (primary) allogeneic stem cell transplantation (alloSCT). This study concluded that front-line alloSCT is effective in these patients. Some background Chemoimmunotherapy containing rituximab (Rituxan) is the typical front-line...
Read MoreEvaluating the long-term outcomes of Zevalin for patients with advanced B cell lymphoma
In a nutshell This study evaluated the long-term outcomes of patients with advanced (stage 3 – 4) non-Hodgkin’s lymphoma (NHL) who received radioimmunotherapy before allogeneic stem cell transplantation (alloSCT). This study concluded that this treatment regimen improved survival in most of these patients. Some background AlloSCT involves...
Read MoreSafety and effectiveness of the biosimilar CT-P10 compared to rituximab in patients with follicular lymphoma
In a nutshell This study looked at the safety and effectiveness of CT-P10 (Truxima) compared to rituximab (Rituxan) in the treatment of follicular lymphoma. Researchers found that CT-P10 had similar safety and effectiveness as rituximab in these patients. Some background Lymphoma is a cancer of the immune system. It is often treated with drugs...
Read MoreEvaluating a new targeted therapy with or without itacitinib for relapsed or refractory lymphoma
In a nutshell This study evaluated the safety and effectiveness of a new targeted therapy (INCB040093) with or without itacitinib in patients with relapsed or refractory (does not respond to treatment) lymphoma. This study concluded that this new agent was well-tolerated and showed promising effectiveness in these patients. Some background...
Read MoreEvaluating brentuximab vedotin plus gemcitabine in children and young adults with relapsed or refractory Hodgkin’s lymphoma
In a nutshell This study evaluated the safety and effectiveness of brentuximab vedotin (Adcetris) plus gemcitabine (Gemzar) in children and young adults with relapsed or refractory (does not respond to treatment) Hodgkin’s lymphoma (HL). This study concluded that this combination is safe and shows promising effectiveness in these...
Read MoreEvaluating outcomes after radiotherapy and PET/CT scanning for patients with follicular lymphoma
In a nutshell This study evaluated the outcomes of patients with localized (cancer has not spread to other parts of the body) early-stage follicular lymphoma (FL) after positron emission tomography/computed tomography (PET/CT) scanning. This study concluded that radiotherapy is a highly effective treatment for these patients. Some background FL is one...
Read More
